FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE ...
Healio

FDA expands approval for Zoryve cream 0.3% to children with psoriasis as young as 2 years

The FDA approved Zoryve cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years, Arcutis announced ...
MPR

FDA Expands Zoryve Cream 0.3% Approval for Plaque Psoriasis Down to Age 2

The FDA has approved an expanded indication for Zoryve (roflumilast) cream 0.3% to include plaque psoriasis in pediatric patients aged 2 years and older.